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 It is believed that Tongkat Ali can improve erectile dysfunction (ED) in Asian men 
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 A subgroup analysis suggested Tongkat Ali may improve ED among more severe ED cases 
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ABTRACT 
 
Objective: To determine the efficacy of Tongkat Ali (Eurycoma longifolia) herbal extract on erectile 
function improvement. 
Methods: Comprehensive electronic databases were searched from inception through October 2014. 
Randomized controlled trials investigating Tongkat Ali compared to placebo were included. Outcome of 
interest was the improvement of erectile dysfunction. The difference of changes from baseline of the 
outcome between Tongkat Ali and placebo was pooled using weighted mean difference (WMD). 
Methodological quality of included studies was assessed using Jadad’s quality scale and Cochrane’s risk 
of bias.  
Results: Of the 342 articles identified, 2 studies involving a total of 139 participants were analyzed. No 
significant between group difference was found in the mean WMD of the change in the 5-item version of 
the International Index of Erectile Function (IIEF-5) at week-12 (0.91; 95% CI: -1.50 to 3.33 with I2 = 
89.5%, P-value = 0.002) with statistical heterogeneity. Based on the subgroup analysis, significant 
improved IIEF-5 score of 2.15 (95% CI 1.03 to 3.27) was found in subjects with lower baseline IIEF-5 
score, but this was not seen among those with higher baseline IIEF-5 score. 
Conclusion: Based on current evidence, the herbal extract of Tongkat Ali may have clinical effect on 
erectile function. However, more efficacy trials are warranted to further support current evidence.   
 
Key words: tongkat ali; eurycoma longifolia; root; extract; erectile dysfunction; alternative medicine 
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INTRODUCTION 
Sexual health plays an important role in quality of life of both genders. In males, erectile dysfunction (ED) 
can lead to dissatisfaction in sexual life and deterioration of sexual well-being.(1) ED is defined as a 
consistent or recurrent inability of a man to attain and/or maintain penile erection sufficiently for sexual 
activity, which occurs as a result of a lack of blood flow to the penis.(2) ED is an important sexual health 
problem worldwide with the estimated prevalence of 52% among men aged 40–70 years.(1) The 
prevalence of ED increases with age, with the highest prevalence in men in their seventies and eighties of 
between 50%-75%.(1, 2) Surveys among Asian countries showed that the prevalence of self-reported 
moderate ED in aging males (40–70 years) ranging from 17.7%, 22%, 28.3%, 32.2%, and 34% in Taiwan, 
Malaysia, China, Korea, and Japan, respectively.(3) Due to cultural differences in oriental countries 
compared to western countries including taboos and cultural restrictions, most Asian men with ED do not 
seek for formal medical treatment.(4) The Asian MALES study revealed that it was not uncommon for 
Asian men to consider traditional herbal medicine as a potential option to improve their sexual well-
being.(5) 
 
Eurycoma longifolia, from the Simaroubaceae family, is a native herb to the forests in Malaysia, Indonesia, 
and Thailand. It is traditionally known as ‘Tongkat Ali’ among Malaysian, which is believed to enhance 
sexual performance. Tongkat Ali is popular for its aphrodisiac property and has been commonly used as 
an energy enhancer.(6-8) Recent evidences suggest that water extract of the roots of Tongkat Ali can 
enhance testosterone level in men and can improve ED. Even though the mechanism of the effect of 
Tongkat Ali on ED remains unknown, it was postulated that a wide range of bioactive compounds 
including phenolic compounds, polypeptides, diterpenoids, alkaloids, and quassinoids may contribute to 
such effect.(3, 6) However, little is known on the efficacy of Tongkat Ali on aphrodisiac effect in 
human.(9) Using systematic review to summarize clinical evidence of herbal therapy has been considered 
as one of the best tools to synthesize overall findings and to define future research direction for the herbal 
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intervention of interest.(10-12) Therefore, this study aims to determine the effect of Tongkat Ali’s roots 
water extract on the ED performance using systematic review and meta-analysis approach. 
 
METHODS 
Data sources and searching strategy 
This systematic review was conducted according to the Cochrane Collaboration framework guidelines 
(13), and was reported in accordance with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) Statement.(14) The following databases were systematically searched: 
MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov 
and AMED (The Allied and Complementary Medicine Database). Databases were searched from their 
inception to October 10, 2014. Search terms were ‘Tongkat Ali’, ‘Eurycoma longifolia (Jack)’, and ‘pasak 
bumi’. References of relevant articles were examined to identify potential studies not indexed in the above 
databases. Authors of relevant articles were inquired if they were aware of other relevant published or 
unpublished studies. The PICO (participants, interventions, comparators, and outcomes) study question is 
specified to determine the clinical effect of Tongkat Ali’s extract compared to placebo on erectile function 
improvement outcome among male subjects with or without erectile dysfunction.  
 
Inclusion criteria 
The inclusion criteria were the followings: (i) randomized controlled clinical trial (RCT) in human 
subjects and ii) investigating the clinical effect of Tongkat Ali on erectile function. There was no language 
and study design restriction. Studies that were not original articles such as comments, letters, reviews, 
meta-analyses, guideline, case reports, surveys or editorials were excluded. Studies from the same 
population (duplicate studies), not reporting or obtaining effect estimates or with insufficient information 
to compute effect estimates were also excluded.  
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Quality assessment of included study 
Screening for eligibility of all retrieved articles from searching and decision making on studies or clinical 
trials to be included were performed by 2 independent researchers (SK and NC). In addition, the 
methodological quality of each included clinical trial was appraised by them using a scale developed by 
Jadad et al (15) and Cochrane risk of bias criteria.(13, 16) Disagreements between the reviewers were 
resolved by discussion and consensus. The Cochrane risk of bias (16) evaluates bias in intervention 
studies based on a number of criteria including: sequence generation; allocation concealment; blinding; 
incomplete outcome data; selective reporting; and other sources of bias. Studies in which baseline 
characteristics were different among studies groups or not tested for their difference were considered as 
high risk for the domain of ‘other risk of bias’. The overall risk of bias for each study was based on the 
risk of bias of all domains. Each study was classified as having low risk (low risk of bias for all key 
domains), high risk (high risk of bias for one or more key domains), or unclear risk (unclear risk of bias 
for one or more key domains). For Jadad score (15), items for methodology evaluation include random 
allocation, blinding, and description of dropouts and withdrawals. We also determined whether the 
investigators assayed the amount of active ingredients in each Tongkat Ali preparation. 
 
Data extraction and summarizing study results 
Characteristics and results of included studies were extracted by 2 independent researchers (SK and NC), 
using a data extraction form in accordance with the Consolidated Standards of Reporting Trials 
(CONSORT) statement for reporting herbal interventions.(17) We extracted the number and 
characteristics of patients, the amount of Tongkat Ali administered, dosage form of herbal extract, 
duration of intervention, and outcome measurement. ED score measured by IIEF-5 was the outcome of 
interest (lower score implies a higher degree of ED symptoms). Information not available in the included 
studies was enquired directly with the corresponding authors.  
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Statistical analysis 
Data from all studies were pooled in a meta-analysis to determine the overall effect size with 95% 
confidence interval (CI). The effect of Tongkat Ali on IIEF-5 was pooled at week 6 and 12 using WMD. 
In case of baseline imbalance, the difference of changes from baseline of the outcome variables between 
intervention and comparator arms were pooled instead. Statistical heterogeneity between studies was 
assessed using the chi-squared test and I2.(18) A P-value of 0.10 or less indicated heterogeneity between-
studies. I-squared values < 50 % denoted no/minimal heterogeneity across studies.(13) The Dersimonian 
and Laird random-effects model was employed for all analyses.(19) Meta-analyses were conducted using 
STATA version 10 (STATA Corp, College Station, TX, USA). Studies included reported ED scores in 
different forms of standard questionnaires. IIEF-15 was used in Ismail et al and the score was reported for 
intervention arm only. In order to analyze combined scores on ED performance, we requested the 
corresponding author to provide us the IIEF-5 score for both intervention and placebo arms, which is 
obtainable due to 5 question items in IIEF-5 (20) are subset of IIEF-15 question items.(21) 
 
RESULTS 
Study selection 
Our search yielded a total of 342 potential articles. Three hundred and forty studies were excluded because 
they were not RCT (Figure 1). No further published or unpublished studies were identified after 
contacting the experts in the field (Ismail SB, Udani JK). Finally, we included a total of 2 studies 
involving 139 participants in our analysis.(3, 22) 
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Figure 1 Flow chart of the identified articles, the screening and inclusion process. 
 
Study characteristics 
Table 1 gives an overview of all included studies. Both studies were randomized, placebo-controlled trials. 
Subjects were described as healthy American males, aged 40-65 years with stable heterosexual 
relationship in Udani et al (22), and healthy married Malay males aged 30-55 years in Ismail et al (3). 
Both studies did not specify that subjects need to be medically diagnosed with ED as one of their inclusion 
criteria. The average age was reported as approximately 43 years old in Ismail et al, whereas it was not 
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reported in another trial. The baseline IIEF-5 was in the range of 12.36 to 15.77 in Udani et al (22), and 
21.30 to 22.29 in Ismail et al.(3) IIEF-5 score lower than 21 indicates ED. 
 
Both studies used freeze-dried water extract of Tongkat Ali’s root in their trials. Treatment group was 
given 1 tablet of 200 mg of Tongkat Ali root’s extract plus 100 mg Polygonum minus daily in Udani et al 
(22), while two capsules (75 mg) 2 times daily after lunch and dinner (i.e. daily dosage of 300 mg Tongkat 
Ali’s root extract) was administered to treatment group in Ismail et al.(3) Both studies stated that the 
control group received placebo identical to Tongkat Ali. The duration of intervention in both studies was 
12 weeks. No concomitant intervention was given in both studies. Both studies reported no information on 
subject’s adherence assessment. The ED score was assessed using IIEF-5 and compared to baseline value 
at week-6 and week-12.(20, 21) 
 
The primary endpoint of Udani et al (22) was to compare the proprietary Tongkat Ali/Polygonum minus 
combination to placebo with regard to sexual performance, using 6 surveys-the EDITS (Erectile 
Dysfunction Inventory for Treatment Satisfaction) questionnaire, the SIA (Sexual Intercourse Attempts) 
diary and logs, the EHS (Erection Hardness Scale) scale, the SHIM (Sexual Health Inventory 
Questionnaire for Men) questionnaire, the AMS (Aging Male Symptom Score) score, and the IIEF-5 
questionnaire. Primary endpoints of Ismail et al (3) were Quality of Life using SF-36 questionnaire and 
physical fitness tests and the secondary endpoints were Sexual Health Questionnaires (SHQ) for 
measuring overall sexual life and IIEF-15 for measuring ED. Safety endpoints were clinical and laboratory 
measures, for example, complete blood count, comprehensive metabolic panel, urinary analysis, , and 
adverse event monitoring in both studies. All endpoints were measured at week-6 and week-12. 
 
Quality of included studies  
All subjects were randomly allocated into the treatment or control groups. The overall risk of bias within 
the studies yielded that both trials were prone to high risk of bias as outcomes were reported selectively 
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(Table 2). In addition, imbalance of IIEF-5 baseline score between treatment and control arms was 
observed in Udani et al (22) that also resulted in high-risk of bias. Allocation concealment procedure was 
also not reported in both original articles, but correspondences with the authors of both studies revealed 
that random sequence generation, allocation concealment, and blinding procedure were undertaken 
appropriately. Both studies had high Jadad scores: 5 for Udani et al (22) and 4 for Ismail et al.(3) None of 
the included studies reported the amount of active ingredients or the qualitative fingerprint for quality 
assurance of Tongkat Ali preparation. 
 
Table 2 Quality assessment result of included studies. 
Jadad item Udani et al (2014) Ismail et al (2012) 
Q1. Was the study described as randomized? (this includes the use of words such as 
randomly, random, and randomization) 
1 1 
Give 1 additional point if: For Q1., the method to generate the sequence of randomization 
was described and it was appropriate (table of random numbers, computer generated, etc.) 
1 1 
Q2. Was the study described as double blind? 1 1 
Give 1 additional point if: For Q2., the method of double blinding was described and it was 
appropriate (identical placebo, active placebo, dummy, etc.) 
1 1 
Q3. Was there a description of withdrawals and dropouts? 1 0 
Total 5 4 
Risk of bias item Udani et al (2014) Ismail et al (2012) 
Sequence generation Low risk of bias Low risk of bias 
Allocation concealment Low risk of bias Low risk of bias 
Blinding of participants, personnel and outcome assessors  Low risk of bias Low risk of bias 
Selective outcome reporting High risk of bias High risk of bias 
Other sources of bias High risk of bias Low risk of bias 
Overall High risk of bias High risk of bias 
 
Efficacy of Tongkat Ali’s root water extract on erectile dysfunction performance 
The WMD of the effect of Tongkat Ali on IIEF-5 score was not statistically different from the placebo at 
both week-6 (WMD of 1.49 (95% CI: -0.89 to 3.87), I2 = 88.7%, P-value = 0.003) and week-12 (WMD of 
3.11 (95% CI: -1.68 to 7.90), I2 = 97.3.7%, P-value < 0.001) with high heterogeneity. This pooled analysis 
might be invalid because of the significant imbalance of baseline IIEF-5 score between both arms in the 
Page 10 of 17 
 
study of Udani et al (Tongkat Ali arm: 15.770, placebo arm: 12.360).  Therefore, we chose to perform 
meta-analysis based on the changes of IIEF-5 from baseline at week 6 and 12.  
 
At week-6, the WMD of the change of IIEF-5 score was -0.70 (95% CI: -1.49 to 0.09) with I2 = 0%, P-
value = 0.995) without statistical heterogeneity (Table 3). This implies that the effect of Tongkat Ali is not 
statistically significant after 6 weeks of therapy. At week-12, the WMD of the change of IIEF-5 score was 
0.91 (95% CI: -1.50 to 3.33) with I2 = 89.5%, P-value = 0.002) with statistical heterogeneity (Table 3). 
The potential cause of this heterogeneity was the lower mean baseline IIEF-5 score of 15.77 and 12.36 in 
Udani et al (22), compared to 22.29 and 21.30) in Ismail et al.(3) In subjects with lower baseline IIEF-5 
score (22), the effect of Tongkat Ali on IIEF-5 score was clearly demonstrated with an increase in IIEF-5 
score of 2.15 (95% CI: 1.03 to 3.27) in Udani et al (22), while there is a lack of effect of Tongkat Ali 
among those who have higher baseline score as shown in Ismail et al.(3)  
 
Adverse effects of Tongkat Ali’s root water extract 
Safety outcomes were reported in both studies and no significant differences of adverse events were found 
between treatment and placebo groups.(3, 22) No serious adverse events were report from Udani et al (22) 
while one subject was hospitalized in Ismail et al (3) under the treatment group, but it was not due to 
treatment.  
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Table 1 Description of randomized controlled trials of Tongkat Ali for erectile function. 
Authors (Year) Target population Tongkat Ali Control Outcome of interest Assessment tool 
Udani et al (2014) 40-65 years old healthy American males 
with stable heterosexual relationship 
200 mg + 100 mg of Polygonum minus Physta 
tablet# 
Identical tablet ED score at week-6 and week-12 
compared to baseline 
IIEF-5 or SHIM## 
Ismail et al (2012)  30-55 years old healthy Malay males 300 mg Physta capsule† Matching capsule ED score at week-6 and week-12 
compared to baseline 
IIEF-15†† 
# Proprietary freeze-dried water extract of Tongkat Ali (Eurycoma longifolia) root plus 100 mg of Polygonum minus 
† Freeze-dried water extract of Tongkat Ali (Eurycoma longifolia) root 
## 5 items of International Index of Erectile Function (IIEF) or Sexual Health Inventory for Men (SHIM) questionnaire with 0-5 rating scale (maximum score = 25) 
†† 15 items of International Index of Erectile Function (IIEF) questionnaire, consisted of 6 items of erectile function score with 0-5 rating scale (maximum score = 30) 
 
Table 3 IIEF-5 outcomes of meta-analysis measured in clinical trial of Tongkat Ali with adjusted baseline imbalance. 
Authors and Year Udani et al 2014 Ismail et al 2012 
Group Tongkat Ali Control Tongkat Ali Control 
Subject (n) 12 14 52 50†† 
Comparison week-0 VS week-6     
   Week-0; IIEF-5 score in Mean (SD) 15.770 (1.320) 12.360 (1.450) 22.289 (2.782) 21.300 (3.066) 
   Week-6; IIEF-5 score in Mean (SD) 16.920 (1.460) 14.210 (1.560) 21.423 (2.739) 21.140 (2.893) 
   Difference from baseline† 1.150 (1.392) 1.850 (1.506) -0.865 (2.761) -0.160 (2.980) 
   Mean difference (within trial) -0.70 (-1.81, 0.41) -0.71 (-1.81, 0.42) 
   Pooled WMD (95% CI, I2 , P-value) -0.70 (-1.49 to 0.09, 0.0%, 0.995) 
Comparison week-0 VS week-12     
   Week-0; IIEF-5 score in Mean (SD) 15.770 (1.320) 12.360 (1.450) 22.289 (2.782) 21.300 (3.066) 
   Week-12; IIEF-5 score in Mean (SD) 19.850 (1.210) 14.290 (1.810) 22.173 (2.534) 21.500 (2.830) 
   Difference from baseline† 4.080 (1.266) 1.930 (1.640) -0.115 (2.661) 0.200 (2.950) 
   Mean difference (within trial) 2.15 (1.03, 3.27) -0.32 (-1.41, 0.78) 
   Pooled WMD (95% CI, I2 , P-value) 0.91 (-1.50 to 3.33, 89.5%, 0.002) 
†SD = Standard deviation (Pooled SD is based on the formulae:  
††Requested data on mean and SD from author of the study due to no report in the original article 
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DISCUSSION 
This study summarizes evidence from randomized, placebo-controlled trials evaluating the efficacy of 
Tongkat Ali herbal for improvement of ED among men participants. In this meta-analysis, we did not find 
a significant effect of Tongkat Ali extract on ED. The results suggest that the subgroup of subjects with 
more severe ED may benefit from Tongkat Ali extract, but this would need to be confirmed in further 
well-designed studies in humans. 
 
Recent evidence suggest that based on animal studies and anecdotal evidence in humans (9), Eurycoma 
logifolia increases sexual desire, coitus attempts and testosterone levels. Therefore, its extract as herbal 
medicine may help improving erectile function especially among more severe cases which was revealed in 
subgroup analysis. However, the 2.15 points increment of IIEF-5 score is not met the minimal clinically 
important difference (MCID) because the MCID for mild to moderate ED severity baseline (15.77 for 
treatment and 12.36 for placebo) in Udani et al’s study should be at least 5 points increment.(23) IIEF-5 
scores were classified into five ED severity including severe (5 to7), moderate (8 to 11), mild to moderate 
(12 to 16), mild (17 to 21) and no ED (22 to 25).(24) In addition, there remains unclear which active 
compounds are responsible for such effect. A wide range of bioactive compounds including phenolic 
compounds, polypeptides, diterpenoids, alkaloids, quassinoids, and others (3, 6) have been isolated from 
Tongkat Ali. Furthermore, it is important to note that there is no report on any standardized assay to 
quantify the amount of those ingredients in Tongkat Ali preparations used in the included studies.(3, 22)  
 
There are a number of possible reasons that could explain the differences of findings of both studies 
(significant improvement of ED score at week 12 in Udani et al while no significant improvement in 
Ismail et al). Firstly, they use different formulation of investigational herbal medicine. Secondly, the 
subjects in Ismail et al have lower severity of ED, compared to that of Udani et al. The baseline IIEF-5 
score was higher in Ismail et al (22.29 for treatment and 21.30 for control) indicating low ED severity, 
compared to Udani et al (15.77 for treatment and 12.36 for placebo) indicating moderate ED severity.  
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Lastly, another reason is that participants’ ages were not comparable between the two studies. Subjects 
recruited in Ismail et al aged 30-55 years with the average age around 43, while Udani et al recruited 
males aged 40-65 years with no reported average age. In addition, participants with different culture (i.e. 
western and oriental) may respond differently to standardized questionnaires used in the trials. 
 
It might be argued that the benefits seen in trial are not due to Tongkat Ali since Polygonum minus’s 
ingredient was included in the study product by the most recent clinical trial.(22) However, the effect of 
Polygonum is demonstrated mostly as antioxidant (25, 26) without any effect on ED performance.  
However, it cannot be concluded that the effect on ED performance is solely from Tongkat Ali in this trial 
as well, although Tongkat Ali could be the compound contributing to such benefit.  
 
Our study was undertaken in accordance with high standard of systematic review and meta-analysis and 
reported aligned with PRISMA.(27) At review level, our search was as comprehensive as possible. There 
were no further published or unpublished studies identified by the experts in the field (Ismail SB, Udani 
JK). The quality assessment was done using standard approaches (15, 16) which revealed some bias 
(Table 2) in both included studies. At outcome level, both included studies were prone to high risk of bias 
as outcomes were reported selectively and no report on amount of active ingredients or the qualitative 
fingerprint for quality assurance of Tongkat Ali preparation. These gaps or caveats are needed to be 
addressed in order to define a reliable of Tongkat Ali’s efficacy.   
 
In summary, based on the results of our review, it suggests that Tongkat Ali’s root water extract may have 
a clinical benefit on improving ED performance. However, further evidence of efficacy trial is warranted 
to make any firm recommendation. Monitoring of adverse events should be undertaken to ensure safety of 
the product. The potential of Tongkat Ali as an effective herbal ED treatment will be elucidated, when 
more future evidence data based on rigorous RCT is available. 
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